Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD

DOI: 10.1634/theoncologist.2016-0104

Keywords: Multiple myeloma, Survival analysis, Electronic health records, Retrospective studies

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text